ADX-71149 explained

ADX-71149, also known as JNJ-40411813 and JNJ-mGluR2-PAM, is a selective positive allosteric modulator of the mGlu₂ receptor.^{[1] [2] [3]} It is being studied by Addex Therapeutics and Janssen Pharmaceuticals for the treatment of schizophrenia.^[4] It was also researched by these companies for the treatment of anxious depression (major depressive disorder with anxiety symptoms),^[5] but although some efficacy was observed in clinical trials, it was not enough to warrant further development for this indication.^[6], ADX-71149 is in phase II clinical trials for schizophrenia.^[4]

See also

• Biphenylindanone A
• Eglumegad
• LY-404,039
• LY-379,268
• LY-487,379

External links

• ADX71149 for Schizophrenia - Addex Therapeutics
• ADX71149 for Anxiety - Addex Therapeutics
• ADX 71149 - AdisInsight

Notes and References

1. Cid JM, Tresadern G, Duvey G, Lütjens R, Finn T, Rocher JP, Poli S, Vega JA, de Lucas AI, Matesanz E, Linares ML, Andrés JI, Alcazar J, Alonso JM, Macdonald GJ, Oehlrich D, Lavreysen H, Ahnaou A, Drinkenburg W, Mackie C, Pype S, Gallacher D, Trabanco AA . 6 . Discovery of 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): a novel positive allosteric modulator of the metabotropic glutamate 2 receptor . Journal of Medicinal Chemistry . 57 . 15 . 6495–512 . August 2014 . 25032784 . 10.1021/jm500496m .
2. Lavreysen H, Ahnaou A, Drinkenburg W, Langlois X, Mackie C, Pype S, Lütjens R, Le Poul E, Trabanco AA, Nuñez JM . 6 . Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptor . Pharmacology Research & Perspectives . 3 . 1 . e00096 . February 2015 . 25692015 . 4317228 . 10.1002/prp2.96 .
3. Lavreysen H, Langlois X, Donck LV, Nuñez JM, Pype S, Lütjens R, Megens A . Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813 . Pharmacology Research & Perspectives . 3 . 2 . e00097 . March 2015 . 25692027 . 4324682 . 10.1002/prp2.97 .
4. Walker AG, Conn PJ . Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics . Current Opinion in Pharmacology . 20 . 40–5 . February 2015 . 25462291 . 4318747 . 10.1016/j.coph.2014.11.003 .
5. Dunlop J, Brandon NJ . Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations? . Journal of Psychopharmacology . 29 . 2 . 230–8 . February 2015 . 25586401 . 10.1177/0269881114565806 . 42542103 .
6. Web site: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder (MDD) with Significant Anxiety Symptoms . Addex Therapeutics . 7 February 2014 . 24 May 2015 . https://web.archive.org/web/20150525040202/http://www.addextherapeutics.com/investors/press-releases/news-details/article/addex-reports-top-line-data-from-adx71149-phase-2a-study-in-patients-with-major-depressive-disorder/ . 25 May 2015 . dead .